Related Experiment Video

Updated: Jul 12, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Plasma level of cardiotrophin-1 as a prognostic predictor in patients with chronic heart failure

Takayoshi Tsutamoto1, Shigeru Asai, Toshinari Tanaka

  • 1Department of Cardiovascular Medicine, Shiga University of Medical Science, Seta-Tsukinowa, Otsu, 520-2192, Japan. tutamoto@belle.shiga-med.ac.jp

European Journal of Heart Failure
|September 4, 2007
PubMed

Insights

Cardiotrophin-1 (CT-1) and brain natriuretic peptide (BNP) levels predict mortality in chronic heart failure (CHF). Combined CT-1 and BNP measurements offer superior accuracy for predicting CHF patient mortality.

Area of Science:

  • Cardiology
  • Biomarkers
  • Heart Failure Research

Background:

  • Cardiotrophin-1 (CT-1) is an interleukin-6 (IL-6) family cytokine.
  • Elevated CT-1 levels are observed in patients with chronic heart failure (CHF).

Purpose of the Study:

  • To investigate the prognostic significance of CT-1 in patients diagnosed with CHF.
  • To determine if CT-1 improves mortality prediction in CHF patients.

Main Methods:

  • Plasma levels of CT-1, BNP, and IL-6 were measured in 125 CHF patients.
  • Patients were followed for a mean of 2.9 years to track mortality.
  • Statistical analysis, including stepwise multivariate analysis, was employed.

Main Results:

  • CT-1 plasma levels correlated negatively with left ventricular ejection fraction and positively with IL-6.
  • Higher CT-1, BNP, and IL-6 levels independently predicted mortality in CHF patients.
  • Combined high CT-1 and BNP levels significantly increased mortality risk (HR 2.48).

Conclusions:

  • Plasma CT-1 measurement provides valuable prognostic information for CHF.
  • Combining CT-1 and BNP levels enhances the accuracy of mortality prediction in CHF patients compared to individual markers.
Abstract

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...